Infinity Pharma adds another bull at JPMorgan on potential of cancer therapy
Adam Gault/OJO Images via Getty Images
- Infinity Pharmaceuticals (NASDAQ:INFI) has climbed ~17.9%
in the pre-market after JP Morgan upgraded the stock to overweight from neutral, citing the prospects of eganelisib, the company’s oral candidate currently…
